Compare Crispr Therapeutics AG (CRSP) vs CSX Corporation (CSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs CSX Corporation — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while CSX Corporation trades at $50.1 (market cap $92.55B). The key difference: CSX Corporation is far larger — about 17.7× Crispr Therapeutics AG's market cap, and CSX Corporation pays a 1.12% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | CSX | |
|---|---|---|
Market Cap | $5.23B | $92.55B |
Sector | Health | Industrials |
52-Week High | $76.78 | $53.21 |
52-Week Low | $44.34 | $32.05 |
Enterprise Value | $3.65B | $110.52B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
CSX trades at $50.12, down 0.3% on the day, with a neutral technical signal. Recent Q2 2026 earnings beat estimates with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and margin expansion. The stock's valuation ratios, including a P/E of 29.05 and P/S of 6.41, reflect a premium pricing relative to historical levels. Analyst consensus is bullish with a $52.57 price target, supported by 58.69% buy ratings.
The outlook for CSX is positive, with projected 2026 revenue growth and improved cash flow. Key opportunities include strong intermodal demand and operational efficiency gains. Risks involve competitive pressures, fuel cost volatility, and potential economic slowdowns affecting freight volumes. The stock's current level offers a moderate upside to the consensus target, balanced by elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
